Physicians' Academy for Cardiovascular Education

Effect of dietary supplements on LDL-c compared with low-dose statin and placebo

News - Nov. 7, 2022

Effect of Low-Dose Statin Compared With Placebo and Six Dietary Supplements on Lipid and Inflammatory Biomarkers: The SPORT Randomized Clinical Trial

Presented at the AHA Scientific Sessions 2022 by: Luke J. Laffin, MD - Cleveland, OH, USA

Introduction and methods

In the SPORT (Supplement, Placebo, or Rosuvastatin Study) trial, the effect of several widely used dietary supplements on lipid and inflammatory biomarkers was investigated. For this prospective, single-center, single-blind RCT, 199 participants were randomized to receive 1 dietary supplement (fish oil, cinnamon, garlic, turmeric, plant sterols, or red yeast rice) or placebo or rosuvastatin 5 mg daily. Inclusion criteria were: 40–75 years of age, no established ASCVD, LDL-c level of 70–189 mg/dL, and 10-year ASCVD risk of 5%–20%.

At days 0 and 28, a lipid panel, a comprehensive metabolic panel, and hs-CRP were measured. The primary endpoint was the percent change in LDL-c level from day 0 to day 28. Secondary endpoints included percent change in lipid and inflammatory biomarkers between baseline and day 28.

Main results


In individuals with an increased 10-year ASCVD risk but no established ASCVD, rosuvastatin 5 mg daily outperformed 6 widely used dietary supplements (fish oil, cinnamon, garlic, turmeric, plant sterols, and red yeast rice) and placebo in terms of LDL-c reduction. It also lowered total cholesterol and triglycerides more than the any of the supplements or placebo did, and had similar low rates of adverse events.

-Our reporting is based on the information provided at the AHA Scientific Sessions-

Share this page with your colleagues and friends: